News und Analysen

A clutch of post-earnings price target increases by analysts helped raise Medtronic's (NYSE: MDT) stock at a healthy rate on Wednesday. The sturdy medical device specialist's shares rose by almost

Premier (NASDAQ:PINC), a leading provider of healthcare supply chain and performance improvement solutions, reported its fiscal fourth-quarter results on August 20, 2025, for the period ended June

Shares of Viking Therapeutics (NASDAQ: VKTX) rose by almost 10% at 11 a.m. ET today. This follows a significant fall the previous day on the release of its eagerly awaited top-line results from a

Image source: The Motley Fool.

Wednesday, August 20, 2025 at 10 a.m. ET

Chairman, President, and Chief Executive Officer — Vincent Roche

Continue reading

Source Fool.com

The average healthcare stock has a yield of just 1.8%, which isn't much to write home about today. You can do much better than that with Medtronic (NYSE: MDT), currently yielding 3%, or if you're

What's better than a stock that pays great dividends? How about one that's also a bargain? Granted, most strong dividend stocks aren't available at a discount in the current high-flying market

Vertex Pharmaceuticals (NASDAQ: VRTX) has been a top pharma stock in recent years. It has been generating strong revenue growth while also building out its portfolio of drugs, expanding its growth

Shares of health insurer UnitedHealth Group (NYSE: UNH) received a boost last week after investors learned that Warren Buffett's company, Berkshire Hathaway (NYSE: BRK.A)(NYSE: BRK.B), has invested

What the stock analysis community giveth, it can also taketh away.

That was the dynamic behind the slide of UnitedHealth Group (NYSE: UNH) stock on Tuesday. As in the previous trading session, the

Nvidia (NASDAQ: NVDA) shares fell 3.5% on Tuesday, closing at $175.64, as tech stocks broadly pulled back following a recent rally. The chipmaker traded 183 million shares, just above its

Medtronic (NYSE: MDT) stock had declined 3.6% through 2:45 p.m. ET Tuesday despite beating forecasts for fiscal 2026 first-quarter earnings this morning.

Heading into the report, analysts predicted

Viking Therapeutics (NASDAQ: VKTX) stock collapsed in morning trading Tuesday, down more than 40% after reporting mixed results for its GLP-1 weight loss pill VK2735. As Viking shares plummet

Viking Therapeutics (NASDAQ: VKTX) stock collapsed on Tuesday, down 41.4% through 10:25 a.m. ET after reporting what pharmaceutical analysts are calling "mixed results" for its new GLP-1 weight loss

Viking Holdings(NYSE:VIK) reported second-quarter 2025 earnings on August 19, 2025, achieving 18.5% year-over-year revenue growth to $1.9 billion, an adjusted EBITDA increase of 28.5% to $633

Premier(NASDAQ:PINC) reported fourth quarter and full-year 2025 results on August 19, 2025, with revenue of $986 million and adjusted EPS of $1.54, both exceeding guidance. The company’s Supply

Medtronic (NYSE:MDT), a global medical technology leader specializing in cardiovascular, neuroscience, and surgical devices, reported Q1 FY2026 earnings on August 19, 2025. The most notable news

UnitedHealth Group (NYSE: UNH) has been a staple in the healthcare world for decades and is one of the largest companies in the world, with a market cap of around $280 billion as of Aug. 18

Finding a high-yielding stock that is safe to hang on to can be a rarity. When yields get high (e.g., more than 5%), usually there's a reason behind it. And investors are often hesitant to invest in

Space and defense stock Voyager Technologies (NYSE: VOYG) took off like a rocket packed with fuel on Monday. The company's shares gained more than 13% in value after it divulged an investment into

Good news from a peer and a positive analyst update were the elements driving Viking Therapeutics (NASDAQ: VKTX) stock higher on the first trading day of the week.

The clinical-stage biotech

UnitedHealth Group (NYSE: UNH), by far the health insurance stock that's gotten most of the market's attention over the past few trading sessions, had a good Monday on the exchange. Its shares added

AbbVie (NYSE: ABBV) became a stand-alone, publicly traded company when it split from its former parent, Abbott Laboratories, in 2013. The reason for the split was for each company to generate

Pharmaceutical companies regularly encounter substantial headwinds. Among the most significant are patent cliffs -- when therapies lose patent exclusivity, inviting cheaper generic or biosimilar

Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares